Related Experiment Video
Updated: Nov 25, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's
Roiya Farhan1, Nof S Alqarni2, Ali H Algiraigri2
1Department of Pediatrics, King Fahad Military Medical City, Dhahran, KSA.
Abstract:
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare but distinct subtype of Hodgkin's lymphoma (HL) that carries a better prognosis than classical Hodgkin's lymphoma. Historically, both subtypes of Hodgkin's lymphomas (classical HL and NLPHL) have been grouped together and treated as classical Hodgkin's lymphoma. Recent studies have questioned this approach and have called for an alternative method due to expected severe long-term adverse events. We report two cases of NLPHL that were successfully treated with reduced chemotherapy cycles, as well as rituximab, in the form of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone).
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Treatment Resistant Cancers

